These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Suspecting and diagnosing transthyretin amyloid cardiomyopathy (ATTR-CM) in India: An Indian expert consensus. Chander Mohan J; Dalal J; Chopra VK; Narasimhan C; Kerkar P; Oomman A; Ray Fcsi S; Sharma AR; Dougall P; Simon S; Verma Drm A; Radhakrishnan V Indian Heart J; 2022; 74(6):441-449. PubMed ID: 36410415 [TBL] [Abstract][Full Text] [Related]
30. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). Maurer MS; Hanna M; Grogan M; Dispenzieri A; Witteles R; Drachman B; Judge DP; Lenihan DJ; Gottlieb SS; Shah SJ; Steidley DE; Ventura H; Murali S; Silver MA; Jacoby D; Fedson S; Hummel SL; Kristen AV; Damy T; Planté-Bordeneuve V; Coelho T; Mundayat R; Suhr OB; Waddington Cruz M; Rapezzi C; J Am Coll Cardiol; 2016 Jul; 68(2):161-72. PubMed ID: 27386769 [TBL] [Abstract][Full Text] [Related]
31. Prevalence, Incidence, and Impact on Mortality of Conduction System Disease in Transthyretin Cardiac Amyloidosis. Donnellan E; Wazni OM; Saliba WI; Hanna M; Kanj M; Patel DR; Wilner B; Kochar A; Jaber WA Am J Cardiol; 2020 Aug; 128():140-146. PubMed ID: 32650908 [TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Damy T; Garcia-Pavia P; Hanna M; Judge DP; Merlini G; Gundapaneni B; Patterson TA; Riley S; Schwartz JH; Sultan MB; Witteles R Eur J Heart Fail; 2021 Feb; 23(2):277-285. PubMed ID: 33070419 [TBL] [Abstract][Full Text] [Related]
33. Clinical recommendations to diagnose and monitor patients with transthyretin amyloid cardiomyopathy in Asia. Lin W; Chattranukulchai P; Lee AP; Lin YH; Yu WC; Liew HB; Oomman A Clin Cardiol; 2022 Sep; 45(9):898-907. PubMed ID: 35795903 [TBL] [Abstract][Full Text] [Related]
34. Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis. Antonopoulos AS; Panagiotopoulos I; Kouroutzoglou A; Koutsis G; Toskas P; Lazaros G; Toutouzas K; Tousoulis D; Tsioufis K; Vlachopoulos C Eur J Heart Fail; 2022 Sep; 24(9):1677-1696. PubMed ID: 35730461 [TBL] [Abstract][Full Text] [Related]
35. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings. Maia LF; Magalhães R; Freitas J; Taipa R; Pires MM; Osório H; Dias D; Pessegueiro H; Correia M; Coelho T J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):159-67. PubMed ID: 25091367 [TBL] [Abstract][Full Text] [Related]
36. Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT. Nativi-Nicolau J; Judge DP; Hoffman JE; Gundapaneni B; Keohane D; Sultan MB; Grogan M ESC Heart Fail; 2021 Oct; 8(5):3875-3884. PubMed ID: 34432383 [TBL] [Abstract][Full Text] [Related]